The proposed legislation is set to amend various sections of the Arizona Revised Statutes related to health insurance and medical service coverage. By mandating that insurers limit the out-of-pocket cost for epinephrine auto-injectors, the bill addresses a crucial area of concern for individuals who may otherwise face high costs for life-saving medication. Supporting advocates argue that this law will enhance the accessibility of essential medication for those with allergies, ultimately improving public health outcomes in the state.
Summary
House Bill 2596, introduced by Representative Longdon, aims to ensure affordable access to epinephrine auto-injectors by limiting out-of-pocket costs for patients. The bill stipulates that health insurers in Arizona must cover the cost of epinephrine auto-injectors at a maximum price of $30 per thirty-day supply, effective from January 1, 2025. This measure is aimed at protecting individuals with severe allergic reactions and ensuring they have the necessary medical device available without financial burden.
Contention
While the intent behind HB 2596 is largely seen as progressive and beneficial, potential points of contention include concerns from insurance providers regarding the financial implications of the mandated coverage limits. Some industry representatives may argue that such requirements could lead to increased premiums for consumers, or they may raise issues relating to the sustainability of such provisions in the face of changing market dynamics. Additionally, opposition could arise from parties who believe that blanket legislative measures may not adequately address individual circumstances and healthcare access needs.
Mandates health insurance coverage by eliminating out-of-pocket costs for lung cancer screenings in order to enable patients to get the critical care they need without delay.
Mandates health insurance coverage by eliminating out-of-pocket costs for lung cancer screenings in order to enable patients to get the critical care they need without delay.
Mandates health insurance coverage by eliminating out-of-pocket costs for lung cancer screenings in order to enable patients to get the critical care they need without delay.
Extends "Epinephrine Access and Emergency Treatment Act" to include administration of epinephrine auto-injector devices by individuals in possession of devices pursuant to personal prescriptions.